Solicitor General Supports Cert in Amgen v. Sandoz, Supreme Court Denies Cert in Amgen v. Apotex

by Patterson Belknap Webb & Tyler LLP
Contact

Last week, the Solicitor General submitted its brief in Amgen v. Sandoz, arguing that the Supreme Court should review and decide in Sandoz’s favor both questions presented by the parties’ cross-petitions for certiorari.  Two days later, however, the Supreme Court denied cert in Amgen v. Apotex, which raised similar issues.

Amgen v. Sandoz was the Federal Circuit’s first decision interpreting the BPCIA.  The court first addressed the patent dance, the series of back-and-forth pre-suit information exchanges between the biosimilar applicant and the reference product sponsor that the BPCIA says the parties “shall” engage in.  Sandoz, which sought to market (and has since launched) Zarxio, a biosimilar version of Amgen’s Neupogen (filgrastim), did not provide Amgen with the information required to commence the patent dance. Amgen sued, arguing that Sandoz had violated the BPCIA by refusing to provide the statutory information, and also by providing a notice of commercial marketing before its product had been approved.  On appeal, the Federal Circuit held that Sandoz’s decision to opt out of the patent dance did not violate the BPCIA.  However, the Federal Circuit held that Sandoz’s pre-approval notice of commercial marketing was ineffective because the notice must come after FDA licensure of the biosimilar product.  The Federal Circuit enjoined Sandoz from marketing its product during the 180-day post-approval notice period.  Subsequently, in Amgen v. Apotex, the Federal Circuit clarified that the 180-day post-approval period was mandatory and enforceable by an injunction whether or not the biosimilar applicant chose to participate in the patent dance.

Earlier this year, Sandoz filed a petition for cert on the notice of commercial marketing issue.  Amgen opposed Sandoz’s petition and filed a conditional cross-petition on the patent dance issue.  In June, the Supreme Court deferred a decision on cert, instead asking the Solicitor General to weigh in and express the views of the United States.  In September, Apotex filed its own petition for certiorari raising similar questions concerning the BPCIA’s notice of commercial marketing provision as Sandoz raised in its petition.

In its brief of last week, the Solicitor General argues that the Supreme Court should accept review of the petition and cross-petitions in Amgen v. Sandoz and rule for Sandoz on all questions.  First, the SG argues that the notice of commercial marketing can come before the approval of the biosimilar product, as long as it is given at least 180 days before the biological product goes on sale.  In Amgen v. Sandoz, the Federal Circuit reasoned that the notice must come after licensure because the BPCIA refers to a notice for a “licensed” biosimilar product.  The SG disagrees with this reading, arguing that “licensed” merely refers to the status of the biosimilar at the time commercial marketing begins, not at the time the notice is provided.  The SG argues that even though its interpretation means that there may be no time in between approval and marketing to litigate a preliminary injunction, the BPCIA is designed to promote early litigation and affords the parties the opportunity to litigate before marketing.  According to the SG, once notice of commercial marketing is given, “the sponsor can initiate whatever infringement litigation it wants to well before that commercial marketing, and it can do so even if the notice is given at the beginning stages of the regulatory process rather than at the end.”  The SG also argues that the Federal Circuit’s interpretation improperly gives innovators an extra six months of exclusivity on top of the 12 years provided for by the BPCIA.

Second, the SG briefly addresses the availability of an injunction to enforce the BPCIA’s notice of commercial marketing provision.  In Amgen v. Sandoz, the Federal Circuit imposed an injunction to prevent Sandoz from entering the market prior to 180 days after FDA licensure of its biosimilar.  In its subsequent Amgen v. Apotex decision, the Federal Circuit reaffirmed that an injunction was “proper to enforce” the notice of commercial marketing provision.  The Solicitor SG disagrees, arguing that the BPCIA provides no express or implied private right of action to enforce its provisions.  According to the SG, the reference product sponsor’s only recourse if the notice of commercial marketing is not provided is to bring an immediate patent infringement action.

Finally, the SG addresses Amgen’s cross-petition and argues that the Federal Circuit’s holding on the patent dance should be upheld.  The SG agrees with the appellate court’s reasoning that although the BPCIA uses the word “shall,” it specifies a consequence for failure to participate in the pre-suite dispute resolution procedures: forfeiture of the applicant’s right to bring a declaratory judgment action and the ability of the reference product sponsor to immediately commence patent litigation.  The SG takes the position that even if “shall” is read to be mandatory, the sole consequences are those specified in the BPCIA.  The biosimilar applicant may choose not to participate in the patent dance so long as it is willing to accept those consequences.

Coincidentally or not, the SG filed its brief supporting cert in Amgen v. Sandoz two days before the Supreme Court considered Apotex’s related petition in Amgen v. Apotex.  On December 12, the Supreme Court denied Apotex’s petition.  The cross-petitions in Amgen v. Sandoz are still pending.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP
Contact
more
less

Patterson Belknap Webb & Tyler LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.